Estrogen patches are hard to find, and it may not be resolved any time soon

• Estrogen patch prescriptions more than doubled from 594,000 in June 2024 to 1.6 million in May 2025, now representing 44% of all estrogen prescriptions as doctors prefer topical delivery over oral administration for safety reasons
• Manufacturers cite 'unprecedented demand' and face challenges scaling up production because transdermal patches require highly complex manufacturing processes with lower profit margins than brand-name drugs
• Patients and doctors are turning to alternatives including estrogen gels and compounded creams from pharmacies (costing around $50 per month out-of-pocket), while the shortage has spread to other hormone replacement therapies including estradiol creams and progesterone pills

Summary: Estrogen Patch Shortage Threatens Menopause Treatment Access

Key Developments:

Estrogen patches face severe supply constraints as prescriptions surged 162% over two years, reaching 1.6 million in May 2025 from 594,000 in June 2024. Patches now represent 44% of all estrogen prescriptions, while overall estrogen prescriptions increased 78% during the same period.

Market Drivers:

Demand accelerated following the FDA's removal of a 20-year-old black box warning on hormone replacement therapy (HRT) last fall. The warning, stemming from a 2002 study, had discouraged women from using HRT due to perceived cancer and dementia risks. Later analyses found these risks were overstated. Social media advocacy and celebrity endorsements, including Oprah Winfrey, further amplified awareness of menopause treatment options.

Supply Situation:

Three types of estradiol patches are in shortage according to the American Society of Health-System Pharmacists database, though the FDA has not officially declared a shortage. All six manufacturers report operating at full capacity. Key manufacturers mentioned include Zydus, Noven, Amneal, and Sandoz.

Manufacturing Challenges:

Transdermal patches require complex manufacturing processes compared to pills. Generic manufacturers typically run production lines periodically throughout the year, making rapid scaling difficult. Additional complications include new hazardous substance handling regulations and lower profit margins on generic products.

Market Impact:

• Telehealth provider Hims & Hers entered the menopause market 18 months ago; interest tripled since October launch
• Shortages spreading to estradiol creams and progesterone pills
• Compounding pharmacies offering alternatives at ~$50/month (not insurance-covered)
• Industry experts predict 1-2 years before supply-demand equilibrium

Healthcare providers report spending significant daily effort helping patients navigate availability issues.